SYSMEX CORP.UNSP.ADR 1/2 (F:0YX0) — Market Cap & Net Worth
Market Cap & Net Worth: SYSMEX CORP.UNSP.ADR 1/2 (0YX0)
SYSMEX CORP.UNSP.ADR 1/2 (F:0YX0) has a market capitalization of $4.70 Billion (€4.02 Billion) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #3739 globally and #671 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SYSMEX CORP.UNSP.ADR 1/2's stock price €6.45 by its total outstanding shares 623180031 (623.18 Million).
SYSMEX CORP.UNSP.ADR 1/2 Market Cap History: 2021 to 2026
SYSMEX CORP.UNSP.ADR 1/2's market capitalization history from 2021 to 2026. Data shows change from $27.14 Billion to $4.66 Billion (-31.79% CAGR).
SYSMEX CORP.UNSP.ADR 1/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SYSMEX CORP.UNSP.ADR 1/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0YX0 by Market Capitalization
Companies near SYSMEX CORP.UNSP.ADR 1/2 in the global market cap rankings as of May 2, 2026.
Key companies related to SYSMEX CORP.UNSP.ADR 1/2 by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
SYSMEX CORP.UNSP.ADR 1/2 Historical Marketcap From 2021 to 2026
Between 2021 and today, SYSMEX CORP.UNSP.ADR 1/2's market cap moved from $27.14 Billion to $ 4.66 Billion, with a yearly change of -31.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.66 Billion | -13.51% |
| 2025 | €5.39 Billion | -55.69% |
| 2024 | €12.17 Billion | +2.39% |
| 2023 | €11.88 Billion | -10.51% |
| 2022 | €13.28 Billion | -51.07% |
| 2021 | €27.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of SYSMEX CORP.UNSP.ADR 1/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.70 Billion USD |
| MoneyControl | $4.70 Billion USD |
| MarketWatch | $4.70 Billion USD |
| marketcap.company | $4.70 Billion USD |
| Reuters | $4.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SYSMEX CORP.UNSP.ADR 1/2
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematol… Read more